Latest tumor Stories
Based on the results of the trial's pre-specified interim analysis all control patients in the EF-14 phase III trial will be offered the opportunity to cross over to receive Tumor Treating Fields
CARLSBAD, Calif., Nov. 20, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
Late-Breaker Oral Presentation Highlights Favorable Safety, Tolerability and Pharmacokinetic Profile for TVB-2640 BARCELONA, Spain, Nov.
The order in which a proposed new treatment combination is administered to mesothelioma patients appears to impact effectiveness and tumor regrowth. Raleigh,
- Data include results from a Phase 1 study of ABT-414 as monotherapy and in combination with radiation and/or chemotherapy in patients with newly diagnosed and recurrent/unresectable glioblastoma
Results Published in Cancer Epidemiology, Biomarkers & Prevention Demonstrate Utility of Caris Molecular Intelligence(TM) in Exploring Expression of Targetable Immune Proteins IRVING,
Research shows promise for increasing effectiveness of chemo and reduction of metastasis DALLAS, Nov.
Interim analysis of the pivotal phase III trial of Tumor Treating Fields in newly diagnosed glioblastoma (EF-14) will be presented as a late-breaking oral presentation ST.
Results presented in poster presentation beginning today and in oral presentation Saturday, November 8, at 1:40 PM at Society for Immunotherapy of Cancer annual meeting. ANN ARBOR,
- An armed gangster.